Subscribe To
X4 Pharmaceuticals Reports Second-Quarter 2023 Financial Results, Provides Corporate Updates, and Reports Emerging Data from Chronic Neutropenia Clinical Program
Submission of first U.S. New Drug Application for mavorixafor in WHIM syndrome on track for early 2H 2023 Emerging data from ongoing Phase 2 trial in certain chronic neutropenic disorders show mavorixafor durably increased neutrophil counts and enabled reductions in G-CSF dosing New market research confirms significant initial target population for mavorixafor given high unmet needs within […] The post X4 Pharmaceuticals Reports Second-Quarter 2023 Financial Results, Provides Corporate Updates,...
Read More
Posted: Aug 10 2023, 10:05
Author Name: forextv
Views: 022219